Randomized Phase II Trial of Sipuleucel T Immunotherapy Preceded by Sensitizing Radiation Therapy and Sipuleucel-T Alone in Patients With Castrate Resistant Metastatic Prostate Cancer
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 31 Dec 2019 Status changed from active, no longer recruiting to completed.
- 20 Jun 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 11 Dec 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.